Ponatinib in chronic myeloid leukaemia: ready for first-line?

被引：0
|
作者：
Breccia, Massimo [1 ]
Alimena, Giuliana [1 ]
机构：
[1] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00161 Rome, Italy
来源：
LANCET HAEMATOLOGY | 2015年 / 2卷 / 09期
关键词：
FOLLOW-UP; IMATINIB;
D O I：
10.1016/S2352-3026(15)00130-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E352 / E353
页数：2
相关论文
共 50 条
  • [31] Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: A retrospective analysis
    Thota, N. K.
    Gundeti, S.
    Linga, V. G.
    Coca, P.
    Tara, R. P.
    Raghunadharao
    INDIAN JOURNAL OF CANCER, 2014, 51 (01) : 5 - 9
  • [32] InfliximabTuberculosis and first report of chronic myeloid leukaemia: case report
    Reactions Weekly, 2005, 1046 (1) : 14 - 15
  • [33] Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
    Breccia, M.
    Alimena, G.
    CURRENT CANCER DRUG TARGETS, 2012, 12 (04) : 391 - 401
  • [34] A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
    Jabbour, Elias
    Lipton, Jeffrey H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (06) : 646 - 656
  • [35] Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison
    Firwana, Belal
    Sonbol, Mohamad Bassam
    Diab, Maria
    Raza, Shahzad
    Hasan, Rim
    Yousef, Ibrahim
    Zarzour, Ahmad
    Garipalli, Archana
    Doll, Donald
    Murad, M. Hassan
    Al-Kali, Aref
    INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (06) : 1545 - 1553
  • [36] Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial
    Atallah, Ehab L.
    Mauro, Michael J.
    Sasaki, Koji
    Levy, Moshe Y.
    Koller, Paul
    Yang, Daisy
    Laine, Dramane
    Sabo, John
    Gu, Ennan
    Cortes, Jorge E.
    FUTURE ONCOLOGY, 2024, 20 (38) : 3065 - 3075
  • [37] First-Line Therapy for Chronic Lymphocytic Leukemia
    Cherng, Hua-Jay J.
    Jain, Nitin
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (04) : 725 - 738
  • [38] Cost-Utility Analysis of Dasatinib and Nilotinib in Patients With Chronic Myeloid Leukemia Refractory to First-Line Treatment With Imatinib in Thailand
    Kulpeng, Wantanee
    Sompitak, Sumalai
    Jootar, Saengsuree
    Chansung, Kanchana
    Teerawattananon, Yot
    CLINICAL THERAPEUTICS, 2014, 36 (04) : 534 - 543
  • [39] Ponatinib in childhood Philadelphia chromosome-positive leukaemias: an international registry of childhood chronic myeloid leukaemia study
    Millot, Frederic
    Suttorp, Meinolf
    Versluys, Anne B.
    Kalwak, Krzysztof
    Nelken, Brigitte
    Ducassou, Stephane
    Bertrand, Yves
    Baruchel, Andre
    EUROPEAN JOURNAL OF CANCER, 2020, 136 : 107 - 112
  • [40] Clinical Significance of Serum Prohibitin in Chronic Myeloid Leukemia Patients on First-Line Tyrosine Kinase Inhibitors
    Rakha, Nahed Moawad
    Yassin, Heba A.
    Azzazi, Mohamed
    Hegab, Hany M.
    Nabih, Nermeen A.
    Naguib, Mary G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S287 - S287
12345